Cohance Lifesciences Limited has successfully concluded the reconciliation process for security dematerialization for the quarter ending March 31, 2026. The company, through its registrar, KFin Technologies Limited, has verified that all necessary documentation regarding the conversion and processing of equity shares has been duly furnished to the respective depositories. This ensures transparency and compliance with standard market operations for the company’s shareholders and stakeholders.
Quarterly Compliance Update
Cohance Lifesciences Limited has confirmed the successful completion of the security dematerialization and rematerialization processes for the fourth quarter of the financial year, covering the period from January 1, 2026, to March 31, 2026. This process ensures that the records held with the depositories, specifically the National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), are accurate and up to date.
Registrar Verification
The verification was conducted by KFin Technologies Limited, serving as the company’s designated Registrar and Share Transfer Agent. Following a comprehensive review, the agent has certified that all pertinent details concerning share movements and electronic conversions for the quarter were transmitted to the appropriate stock exchanges where the company’s securities are listed. This update underscores the company’s commitment to maintaining efficient and transparent records management for its investors.
Source: BSE
